Renalytix Plc (RNLX)


+0.11 (+7.33%)
Symbol RNLX
Price $1.61
Beta 1.964
Volume Avg. 0.11M
Market Cap 76.491M
Shares () -
52 Week Range 1.05-4.038
1y Target Est -
DCF Unlevered RNLX DCF ->
DCF Levered RNLX LDCF ->
ROE -357.54% Strong Sell
ROA -154.06% Strong Sell
Operating Margin -
Debt / Equity 173.95% Buy
P/E -1.41 Sell
P/B 9.06 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest RNLX news

Mr. James R. McCullough M.B.A.
Health Information Services
NASDAQ Global Market

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.